macrophagic myofasciitis

macrophagic myofasciitis

A recently-described apparently new disease featuring fever, muscle and joint pain, muscle and general weakness and infiltration of the tissues around the muscles by sheets of large, finely-granular MACROPHAGES. The muscle fibres, themselves are minimally affected. The microscopic appearances are unlike those of any previous muscle or fascial disorder. The condition appears to respond to treatment with various combinations of antibiotics and steroids. It was first described by the French physicians and histopathologists Professor R.K. Gerardi, M. Coquet, F-J Authier, P. Laforêt,L. Bélec, D. Figarelle-Branger, J-M Mussini, J-F Pellissier and M. Fardeau.
References in periodicals archive ?
Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle.
Macrophagic myofasciitis: characterization and pathophysiology.
Arthritis, type 1 diabetes, multiple sclerosis, lupus, macrophagic myofasciitis, and autism spectrum disorders are among the autoimmune/ inflammatory conditions linked to aluminum-adjuvanted vaccines.
Yehuda Shoenfeld's [6] group coined the term ASIA, also known as Shoenfeld's syndrome, as an umbrella to describe the clinical conditions of siliconosis, Gulf War syndrome, macrophagic myofasciitis syndrome, sickbuilding syndrome, and postvaccination phenomena which share similar signs or symptoms, some of which are neurological and may be associated with demyelination and the presence of autoantibodies to an adjuvant material.
Observed syndromes associated with Al hydroxide include "macrophagic myofasciitis" (MMF) characterized by diffuse myalgia, chronic fatigue, and cognitive dysfunction, termed "mild cognitive impairment" [38, 40].
Couette et al., "Long-term follow-up of cognitive dysfunction in patients with aluminum hydroxide-induced macrophagic myofasciitis (MMF)," Journal of Inorganic Biochemistry, vol.
However, because of its aluminum-related macrophagic myofasciitis, the application of aluminum hydroxide has not been widely used.
A role for the body burden of aluminium in vaccine-associated macrophagic myofasciitis and chronic fatigue syndrome.
Macrophagic myofasciitis was first reported in 1998.
Macrophagic myofasciitis was first reported by Gherardi et al in 1998.
The researchers call the condition macrophagic myofasciitis (MMF).
A June 2006 muscle biopsy revealed the presence of aluminum, confirming a diagnosis of macrophagic myofasciitis. The aluminum content of five consecutive 24-hour urine samples, taken in May 2007, produced 5903 nmol of aluminum with a mean of 1181 [+ or -] 232 nmol/24 hours.